Sun Pharma posts net loss of Rs 425 cr in Q1 on one-off charge

US sales drop
42%; Rs 950-cr charge related to settlement of antitrust case in US
LATEST
NEWS : Drug
major Sun
Pharmaceutical on Friday reported a consolidated net loss of Rs 425
crore for the quarter ended June 30, mainly due to one-time exceptional item.
The company had posted a net profit
after taxes, share of profit/loss of associates, joint ventures and
non-controlling interests of Rs 2,033.71 crore for the same period a year ago,
Sun Pharmaceutical Industries said in a filing to the BSE.
Consolidated total revenue from
operations of the company stood at Rs 6,208.79 crore for the quarter under consideration
as against Rs 8,256.26 crore for the corresponding period of the previous
fiscal, it added.
The company and one of its wholly
owned subsidiaries entered into settlements with certain plaintiffs in respect
of an antitrust litigation relating to Modafinil in the month of July 2017,
whereby the company agreed to pay an aggregate amount of $147 million, Sun
Pharma said.
"Since this event relates to
the conditions that existed at the end of the reporting period, the
corresponding Indian rupee liability at Rs 950.50 crore has been provided in
the consolidated unaudited financial results and disclosed as an exceptional
item," it added.
Shares of Sun Pharmaceutical
Industries today closed at Rs 451.30 per scrip on the BSE, down 1.92 per cent
from the previous clsoe.
Comments
Post a Comment